Clinical Data Inc

Clinical Data — Investor Presentation (May 2008)

30 slides from Clinical Data's investor presentation, May 8, 2008

  1. Slide 1: Investor Presentation

    1 Investor Presentation Drew Fromkin, President and Chief Executive Officer, Director

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private

  3. Slide 3: Corporate Snapshot

    3 Corporate Snapshot Headquarters Newton, MA NASDAQ CLDA 52 Week Price Range $13.00 to $28.90 Shares Outstanding 20.9 MM Cash (12/31/07) $77 MM

  4. Slide 4: Mission

    4 Mission To develop and commercialize predictive tests and targeted therapeutics from our growing portfolio of proprietary biomarkers of drug response

  5. Slide 5: Company Highlights

    5 Company Highlights Emerging pharmacogenomics pure play Proprietary diagnostics and therapeutics High margins, large markets Regulated and unregulated genomics services Late stage drug candidate Released positive results from Phase III study of Vilazodone, the Company's candidate drug for depressio

  6. Slide 6: CLDA Businesses

    6 CLDA Businesses Proprietary Pharmacogenetic Tests Comprehensive Genomics Services Targeted Therapeutics Mainstream Clinical Care Patients Providers Payers Clinical Trials and Research Biotech/ Pharmaceutical Companies

  7. Slide 7: Expertise and Proprietary Genetic Markers of Drug Response

    7 Expertise and Proprietary Genetic Markers of Drug Response PGxHealth Targeted drugs launched with companion pharmacogenetic tests Companion tests launched as companion or combination product Pharmacogenetic tests launched independently of associated drug Foundation Intellectual Property Developing

  8. Slide 8: PGx Tests and Drugs: Value Proposition

    PGx Tests and Drugs: Value Proposition Pharma PGxDrugs Generic Labs PGxTests Large Large Low Low Large Large Large Large Large Large Huge Moderate Moderate Small Small Large Moderate Small Small Small Yes Yes No No Yes Slowing Increasing Steady Mature Rapid Margin Volume R&D Costs Development Risks

  9. Slide 9: Genetic Biomarker Intellectual Property

    9 Genetic Biomarker Intellectual Property Difficult to Diagnose Diseases or Syndromes Familial Long QT Syndrome Brugada Syndrome Related familial arrhythmogenic disorders Drug Receptors FCGAMMA IIIA (monoclonal antibodies) VKORC1 (warfarin) ADME Genes Transport MDR1, OCT1, MRP1 Metabolism CYP 2B6 CY

  10. Slide 10: Targeted Therapeutic: Vilazodone

    Targeted Therapeutic: Vilazodone

  11. Slide 11: Targeted Therapeutic: Vilazodone

    11 Targeted Therapeutic: Vilazodone Profile: Genetically guided dual serotonergic in development for the treatment of depression Dual mechanism of action (SSRI and 5HT1A partial agonist) Worldwide exclusive license to Vilazodone patent estate from Merck KGaA (now Merck-Serono) Biomarker intellectual

  12. Slide 12: Vilazodone Phase III Study

    Vilazodone Phase III Study Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder (MDD) 8 week, single dose trial Randomized, double-blind placebo controlle

  13. Slide 13: Vilazodone Phase III Study Design

    Vilazodone Phase III Study Design Patients 18-65 years of age with a diagnosis of MDD according to DSM-IV-TR Disease severity assessed by Score on HAM-D17 HAM-D item 1 (depressed mood) score ^ 2 Minimum baseline score of ^ 22 on HAMD17 Week 0 10 mg Week 1 20 mg Week 2 40 mg Week 8 End of Study

  14. Slide 14: Statistical Significance on Primary and Secondary Efficacy Endpoints

    Statistical Significance on Primary and Secondary Efficacy Endpoints Secondary Efficacy Endpoints Secondary Efficacy Endpoints amean +-SD bmean +-SE *least square mean comparison with ANCOVA Table 1. Mean change from baseline at Week 8 (ITT, LOCF)

  15. Slide 15: Separation Between Vilazodone and Placebo Occurs Early in Treatment

    Separation Between Vilazodone and Placebo Occurs Early in Treatment - - ITT, LOCF - - P-values are for comparisons of vilazodone and placebo by ANCOVA Least squares mean change from baseline for MADRS

  16. Slide 16: Vilazodone Appears to be Well Tolerated Over Weeks of Treatment

    Vilazodone Appears to be Well Tolerated Over 8 Weeks of Treatment Number (%) of Patients Number (%) of Patients Number (%) of Patients Number (%) of Patients Number (%) of Patients Number (%) of Patients Vilazodone N=205 Vilazodone N=205 Vilazodone N=205 Placebo N=204 Placebo N=204 Placebo N=204 Adv

  17. Slide 17: A Biomarker Identifies 30% of Patients with Significantly More Improvement

    A Biomarker Identifies 30% of the Patients with Significantly More Improvement After 8 Weeks of Treatment with Vilazodone Vilazodone Vilazodone Placebo Placebo M+ M- M+ M- Na 49 108 39 128 LS-Mean (SE) -19.3 (1.59) -12.4 (1.26) -13.0 (1.86) -11.8 (1.18) 95% CI (LS-Mean) (-22.4, -16.2) (-14.9, -10.0)

  18. Slide 18: A Biomarker Identifies 30% of Patients with Significantly More Improvement

    A Biomarker Identifies 30% of the Patients with Significantly More Improvement After 8 Weeks of Treatment Least square means of observed MADRS total score by week for Biomarker

  19. Slide 19: Vilazodone Development Plan: Milestones

    19 Vilazodone Development Plan: Milestones Second Phase III study of efficacy launched March 2008 Pre-specified analysis of biomarkers Study expected to be completed year-end 2008 Long-term safety study launched December 2007 Will close enrollment 6 weeks ahead of schedule Manufacture of commercial

  20. Slide 20: PGxHealth: Predictive Tests

    PGx:HEALTH" © A DIVISION OF CLINICAL DATA Predictive Tests cuinicaug para

  21. Slide 21: Genetic Testing Landscape

    21 Genetic Testing Landscape Direct-to-consumer Risk for disease Difficult to diagnose diseases with links to treatment Pharmacogenetic tests for drug prescription Examples Marketed by Whole Genome Scans Paternity Vitamins Disease Markers Prostate Cancer Parkinson's Disease Alzheimer's Disease Valua

  22. Slide 22: PGxPredict Tests

    22 PGxPredictTM Tests Improve treatment approach Reduce costs associated with trial and error prescribing Enhance patients' response to drugs early in treatment Reduce side effects

  23. Slide 23: Currently Offered Pharmacogenetic Tests

    (1) Prevalence & incidence rates exclude International markets. Sources: Selected industry and academic publications and resources. Test Long Q/T Cardiology ~100,000 (U.S.) 1/3,000 Disease Incidence/ Prevalence Disease/Therapeutic Area ~2,000,000 (U.S.) Annually Coumadin Rx/Warfarin Cardiology Folli

  24. Slide 24: Pharmacogenetic Tests: Pipeline

    24 Cardiovascular CNS Oncology Inflammatory Diseases Pharmacogenetic Tests: Pipeline

  25. Slide 25: Payer Progress

    Progress since last update on February 28th Now an approved Medicaid provider in 28 states covering 25.3 MM lives, up from 13 states and 9 MM lives. Growing number of BCBS plans developing positive coverage, policies as a result of the positive TEC evaluation and individual plan test review. Approxi

  26. Slide 26: The Genomics Services Company

    The Genomics Services Company(tm)

  27. Slide 27: Overview

    27 Overview High-quality sequencing, gene expression, genotyping and other molecular services worldwide Comprehensive range of services Full range of regulatory compliance Broad customer base, US and international Pharmaceutical, biotech, agricultural, government, academia 19 of top 20 pharmaceutica

  28. Slide 28: Broadest genomics services menu in the industry

    28 Broadest genomics services menu in the industry: Sequencing ABI 3730 Roche 454 GS FLX (new) Genotyping RFLP Mapping Sequenom Luminex Illumina iScanTM System Agilent Microarray aCGH miRNA Affymetrix Microarray Whole Genome Association DNA Analysis DME-T Algynomics Pain Chip Gene Expression Analysi

  29. Slide 29: Third Quarter FY 2008 Summary

    29 Third Quarter FY 2008 Summary Announced on February 14, 2007 Accomplishments reflect the fundamental value and broad applications of CLDA's expertise and intellectual property as well as its emergence as a pure play genomics company Total revenues from continuing operations: $10.5 MM, up 31% from

  30. Slide 30: Fiscal Year 2009 Objectives

    30 Fiscal Year 2009 Objectives Advance Vilazodone development program with target NDA filing of 2009 Drive adoption of proprietary pharmacogenetic tests Leverage new provider sales force Continue payer coverage progress Continue to acquire and develop proprietary genetic markers of drug response to

Clinical Data — Investor Presentation (May 2008) on 6ix